文献速递基础与转化研究流行病学与生物统计

分光光度法测定葡萄糖-6-磷酸脱氢酶活性的系统综述与荟萃分析

Quantification of glucose-6-phosphate dehydrogenase activity by spectrophotometry: A systematic review and meta-analysis.
PubMed 文献 · PLoS Med · 2020-05-14

该研究汇总15,811名个体的数据,量化分光光度法测定G6PD活性的变异。Trinity检测的调整男性中位数在不同研究间为5.7-12.6 U/g Hb。通用100%活性阈值为9.4 U/g Hb,30%活性阈值诊断灵敏度89%-100%,但70%阈值灵敏度降至64%。

要点

  • 分光光度法测定G6PD活性在不同研究间存在显著变异。
  • 通用100%活性阈值为9.4 U/g Hb,对应30%活性阈值为2.8 U/g Hb。
  • 30%活性阈值诊断性能良好,但70%阈值性能受限。

核心结论

  • 分光光度法测定G6PD活性在不同站点间存在显著变异,可能源于实验室方法差异及未测量的人群因素。
  • 检测特异性通用定量阈值在30%活性水平可提供可靠诊断,但研究间变异阻碍了70%水平通用阈值的性能。
  • 建议谨慎比较基于绝对G6PD活性测量值的研究结果。

研究设计与样本

  • 系统综述与荟萃分析,汇总使用G6PD分光光度法的研究个体数据,共纳入15,811名参与者,年龄0-86岁,44.4%为女性。
  • 通过PubMed检索(2018年4月25日)及联系作者获取未发表贡献,排除仅评估已知血液学状况个体、家族研究或细节不足的研究。
  • 使用改编的QUADAS-2工具评估偏倚风险,比较研究间重复性及实验室内/间变异性。

主要发现

  • G6PD正常对照样本中位活性:Trinity检测为10.0 U/g Hb(范围6.3-14.0),Randox检测为8.3 U/g Hb(范围6.8-15.6)。
  • 13项使用Trinity检测的研究中,调整男性中位数(AMM)范围为5.7至12.6 U/g Hb(p < 0.001)。
  • 对照测量方差范围为0.1至1.5 U/g Hb(p < 0.001),重复测量均值变异系数(CV)范围为1.6%至14.9%(p < 0.001)。
  • 通用100%活性阈值定义为9.4 U/g Hb,对应70%活性阈值为6.6 U/g Hb,30%活性阈值为2.8 U/g Hb。
  • 诊断<30% G6PD活性时,研究间灵敏度89%(95% CI: 81%-94%)至100%(95% CI: 96%-100%),特异度96%(95% CI: 89%-99%)至100%(100%-100%);考虑<70%活性时,灵敏度最低降至64%(95% CI: 52%-75%),特异度降至35%(95% CI: 24%-46%)。

关键数值与推荐

  • G6PD活性通用阈值:100%活性为9.4 U/g Hb,70%活性为6.6 U/g Hb,30%活性为2.8 U/g Hb。
  • 诊断<30% G6PD活性时,灵敏度范围89%-100%,特异度范围96%-100%。
  • 诊断<70% G6PD活性时,灵敏度最低64%,特异度最低35%。

临床怎么用

  • 使用分光光度法筛查G6PD缺乏时,应采用检测特异性阈值,避免跨研究直接比较绝对活性值。
  • 在30%活性水平,通用定量阈值可稳健识别严重缺乏个体,支持 Primaquine 或 Tafenoquine 安全用药决策。
  • 对于中间缺乏(<70%活性),通用阈值性能不足,需结合临床评估。

局限性

  • 缺乏协变量数据及研究背景和方法多样性,限制了对研究间异质性 underlying 因素的识别。
  • 未定义适用于所有检测的通用G6PD活性阈值,需检测特异性阈值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The radical cure of Plasmodium vivax and P. ovale requires treatment with primaquine or tafenoquine to clear dormant liver stages. Either drug can induce haemolysis in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, necessitating screening. The reference diagnostic method for G6PD activity is ultraviolet (UV) spectrophotometry; however, a universal G6PD activity threshold above which these drugs can be safely administered is not yet defined. Our study aimed to quantify assay-based variation in G6PD spectrophotometry and to explore the diagnostic implications of applying a universal threshold. METHODS AND FINDINGS: Individual-level data were pooled from studies that used G6PD spectrophotometry. Studies were identified via PubMed search (25 April 2018) and unpublished contributions from contacted authors (PROSPERO: CRD42019121414). Studies were excluded if they assessed only individuals with known haematological conditions, were family studies, or had insufficient details. Studies of malaria patients were included but analysed separately. Included studies were assessed for risk of bias using an adapted form of the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool. Repeatability and intra- and interlaboratory variability in G6PD activity measurements were compared between studies and pooled across the dataset. A universal threshold for G6PD deficiency was derived, and its diagnostic performance was compared to site-specific thresholds. Study participants (n = 15,811) were aged between 0 and 86 years, and 44.4% (7,083) were women. Median (range) activity of G6PD normal (G6PDn) control samples was 10.0 U/g Hb (6.3-14.0) for the Trinity assay and 8.3 U/g Hb (6.8-15.6) for the Randox assay. G6PD activity distributions varied significantly between studies. For the 13 studies that used the Trinity assay, the adjusted male median (AMM; a standardised metric of 100% G6PD activity) varied from 5.7 to 12.6 U/g Hb (p < 0.001). Assay precision varied between laboratories, as assessed by variance in control measurements (from 0.1 to 1.5 U/g Hb; p < 0.001) and study-wise mean coefficient of variation (CV) of replicate measures (from 1.6% to 14.9%; p < 0.001). A universal threshold of 100% G6PD activity was defined as 9.4 U/g Hb, yielding diagnostic thresholds of 6.6 U/g Hb (70% activity) and 2.8 U/g Hb (30% activity). These thresholds diagnosed individuals with less than 30% G6PD activity with study-wise sensitivity from 89% (95% CI: 81%-94%) to 100% (95% CI: 96%-100%) and specificity from 96% (95% CI: 89%-99%) to 100% (100%-100%). However, when considering intermediate deficiency (<70% G6PD activity), sensitivity fell to a minimum of 64% (95% CI: 52%-75%) and specificity to 35% (95% CI: 24%-46%). Our ability to identify underlying factors associated with study-level heterogeneity was limited by the lack of availability of covariate data and diverse study contexts and methodologies. CONCLUSIONS: Our findings indicate that there is substantial variation in G6PD measurements by spectrophotometry between sites. This is likely due to variability in laboratory methods, with possible contribution of unmeasured population factors. While an assay-specific, universal quantitative threshold offers robust diagnosis at the 30% level, inter-study variability impedes performance of universal thresholds at the 70% level. Caution is advised in comparing findings based on absolute G6PD activity measurements across studies. Novel handheld quantitative G6PD diagnostics may allow greater standardisation in the future.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Pfeffer DA, Ley B, Howes RE, et al. Quantification of glucose-6-phosphate dehydrogenase activity by spectrophotometry: A systematic review and meta-analysis. PLoS Med. 2020. PMID: 32407380. doi:10.1371/journal.pmed.1003084

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。